InsiderTrades.com logo

VAXX Insider Trading

Insider Ownership Percentage: 64.06%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Vaxxinity Insider Trading History Chart

This chart shows the insider buying and selling history at Vaxxinity by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Vaxxinity Share Price & Price History

Current Price: $0.00
Price Change: ▼ Price Decrease of -0.0069 (-95.83%)
As of 12/17/2025 03:16 PM ET

This chart shows the closing price history over time for VAXX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Vaxxinity Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/8/2023Movers Lab Fund I Lp PrimeMajor ShareholderSell25,089$1.67$41,898.638,713,663View SEC Filing Icon  
9/6/2023Movers Lab Fund I Lp PrimeMajor ShareholderSell5,308$1.88$9,979.048,759,064View SEC Filing Icon  
1/23/2023Movers Lab Fund I Lp PrimeMajor ShareholderSell405,217$3.35$1,357,476.958,764,372View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Vaxxinity (NASDAQ:VAXX)

82.95% of Vaxxinity stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at VAXX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Vaxxinity Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/7/2024Ieq Capital LLC83,262$71K0.0%N/A0.066%Search for SEC Filing on Google Icon
11/7/2023New York State Common Retirement Fund23,642$32K0.0%-46.4%0.019%Search for SEC Filing on Google Icon
10/31/2023McAdam LLC68,281$94K0.0%+47.4%0.054%Search for SEC Filing on Google Icon
10/24/2023Bank of New York Mellon Corp121,522$0.17M0.0%-14.8%0.096%Search for SEC Filing on Google Icon
10/19/2023Clarius Group LLC20,000$27K0.0%N/A0.016%Search for SEC Filing on Google Icon
8/4/2023American International Group Inc.20,514$52K0.0%N/A0.016%Search for SEC Filing on Google Icon
7/25/2023Raymond James Financial Services Advisors Inc.17,001$43K0.0%+69.7%0.013%Search for SEC Filing on Google Icon
5/3/2023Integrated Wealth Concepts LLC11,000$25K0.0%N/A0.009%Search for SEC Filing on Google Icon
5/2/2023Lincoln National Corp41,070$93K0.0%N/A0.033%Search for SEC Filing on Google Icon
5/1/2023Virtu Financial LLC12,263$28K0.0%-31.3%0.010%Search for SEC Filing on Google Icon
4/24/2023McAdam LLC46,324$0.11M0.0%N/A0.037%Search for SEC Filing on Google Icon
4/21/2023Blue Zone Wealth Advisors LLC27,500$62K0.0%N/A0.022%Search for SEC Filing on Google Icon
4/18/2023ETF Managers Group LLC43,836$100K0.0%+39.5%0.035%Search for SEC Filing on Google Icon
3/23/2023ETF Managers Group LLC31,427$44K0.0%-15.5%0.025%Search for SEC Filing on Google Icon
11/15/2022Prime Movers Lab LLC17,603,276$31.37M22.6%-1.4%13.968%Search for SEC Filing on Google Icon
11/4/2022First Republic Investment Management Inc.199,022$0.39M0.0%N/A0.158%Search for SEC Filing on Google Icon
8/10/2022Clarius Group LLC20,000$31K0.0%N/A0.016%Search for SEC Filing on Google Icon
7/22/2022Truist Financial Corp20,738$33K0.0%N/A0.016%Search for SEC Filing on Google Icon
7/21/2022Hollencrest Capital Management20,000$31K0.0%N/A0.016%Search for SEC Filing on Google Icon
3/10/2022Prime Movers Lab LLC18,027,314$91.02M17.4%N/A14.377%Search for SEC Filing on Google Icon
2/15/2022Adage Capital Partners GP L.L.C.1,001,670$5.62M0.0%N/A0.799%Search for SEC Filing on Google Icon
2/14/2022ETF Managers Group LLC37,884$0.21M0.0%N/A0.030%Search for SEC Filing on Google Icon
2/1/2022FNY Investment Advisers LLC4,847$27K0.0%N/A0.004%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Vaxxinity logo
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.
Read More on Vaxxinity

Today's Range

Now: $0.00
Low: $0.00
High: $0.04

50 Day Range

MA: $0.01
Low: $0.00
High: $0.04

52 Week Range

Now: $0.00
Low: $0.00
High: $0.06

Volume

10,472 shs

Average Volume

10,759 shs

Market Capitalization

$38.02 thousand

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.01